Olivier Brandicourt (Romuald Meigneux, Sipa via AP Images)

UP­DAT­ED Dew­point nabs ex-Sanofi CEO Brandi­court and Bay­er VC chief Eck­hardt for board

Bay­er-part­nered Dew­point Ther­a­peu­tics is adding a pair of big-name phar­ma vets as it looks to make drugs tar­get­ing bio­mol­e­c­u­lar con­den­sates a re­al­i­ty.

The Boston biotech will add for­mer Sanofi CEO Olivi­er Brandi­court and the head of Bay­er’s ven­ture arm, Jür­gen Eck­hardt, to its board. Though both MDs, the pair has held long ca­reers on the busi­ness side of the in­dus­try, which is where their in­sight will be need­ed most, said Dew­point CEO Amir Nashat.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.